| Similar Articles |
|---|
 |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers.   |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development. |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
December 20, 2011
Brian Orelli |
What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice. |
American Journal of Nursing
August 2010
Lomas & Fowler |
Parents and Children with Cystic Fibrosis A survey was conducted to estimate how many adult patients with cystic fibrosis who receive care at centers accredited by the Cystic Fibrosis Foundation also have biological children with the disease. |
The Motley Fool
March 28, 2008
Brian Lawler |
Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug. |
The Motley Fool
September 30, 2009
Brian Orelli |
Call Me a Wimp, but I'm Still Nervous Can the mud Sequenom seems to be running in turn to quicksand? |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
June 10, 2009
Brian Orelli |
Up 58% on No News? What's Going On? There's no concrete reason for the massive increase in Sequenom yesterday. The stock was flat until noon, then it steadily climbed up to the moon in afternoon trading. |
American Family Physician
August 15, 2000 |
Down Syndrome: What You Need to Know When You're Pregnant |
Scientific American
February 2009
Charles Q. Choi et al. |
News Scan Briefs: Weak on the Nano Risk Also: Booby Traps for Bacteria and more... |
The Motley Fool
December 31, 2008
Brian Orelli |
Health Care's Golden Children The whole industry wasn't down this year. |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
The Motley Fool
October 6, 2010
Jeremy Phillips |
Reasons to Sell Sequenom Today Over the past 12 months, Sequenom has risen 115.7% versus an S&P 500 return of 11.3%. Investors in Sequenom have every reason to be proud of their returns. |
The Motley Fool
April 30, 2009
Brian Orelli |
How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome. |
The Motley Fool
August 16, 2011
Jeremy Phillips |
Read This Before You Think About Selling Sequenom I consider a debt-to-equity ratio below 50% to be healthy, though the number varies by industry. Sequenom is currently below this level, at 1.1%. |
Chemistry World
July 31, 2012
Andrew Turley |
New cystic fibrosis drug in EU Ivacaftor, which is marketed under the brand name Kalydeco, won US approval in January. |
Technology Research News
February 25, 2004 |
Nanowires spot DNA mutation Nanowire sensors could eventually be built into labs-on-a-chip that could be used for medical diagnostics and pathogen detection in the field, and for drug discovery. |
The Motley Fool
March 20, 2009
Brian Orelli |
EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe. |
The Motley Fool
July 31, 2010
Rick Aristotle Munarriz |
The Fool Looks Ahead Energy and entertainment stocks will issue earnings reports in the week that lies ahead. |
Chemistry World
February 22, 2011
Amaya Camara-Campos |
Repairing faulty genes Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs. |
Wired
November 2002
David Ewing Duncan |
DNA as Destiny DNA is the book of life. It's also the book of death. In the future we'll all be read cover to cover. Here's what it's like to take the world's first top-to-bottom gene scan. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
January 3, 2011
Travis Hoium |
Inspire Pharmaceuticals Shares Plunged: What You Need to Know The new trading year came in with a loud thud for Inspire Pharmaceuticals when its stock fell 58% this morning. |
The Motley Fool
August 15, 2011
Brian Orelli |
Another Partner, but Still No Data Sequenom signs up a European partner. |
